Teleflex Highlights Advanced Vascular Technologies at CIRSE 2026, Featuring Dynetic™-35 Stent System
Teleflex Incorporated, a global provider of medical technologies, is set to showcase a range of innovative solutions at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 meeting in Copenhagen. The company’s presence at the event underscores its continued focus on developing technologies designed to support healthcare professionals and expand treatment options across minimally invasive vascular procedures.
Among the technologies highlighted by Teleflex is the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System, a device designed to provide physicians with an additional option for treating iliac artery disease. The technology is supported by findings from the investigator-initiated BIONETIC-TRA study, which evaluated the safety and feasibility of using the Dynetic™-35 Stent through a trans-radial approach for the treatment of atherosclerotic iliac artery lesions.
The study included a 30-day follow-up period and was led by Dr. Michael Lichtenberg of Vascular Center Arnsberg in Germany. Its findings provide clinical experience around the use of radial artery access for iliac interventions, an approach that could be particularly relevant for patients in whom conventional femoral access presents additional challenges.
Exploring Alternative Access for Iliac Interventions
Endovascular treatment of iliac artery disease has traditionally relied heavily on common femoral artery access. Although femoral access remains an established approach for vascular interventions, it may present difficulties in certain patient populations.
Advanced age, arterial calcification, existing stenosis and an increased risk of bleeding can complicate femoral access. These considerations can become particularly important when treating patients with advanced peripheral arterial disease or critical limb ischemia, where vascular anatomy and overall patient condition may make conventional access more challenging.
The BIONETIC-TRA study was designed to investigate whether a trans-radial approach could provide a feasible alternative for iliac artery interventions using the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System.
Patients enrolled in the study were at least 18 years old and had iliac artery lesions that could be treated with the Dynetic™-35 Stent. Eligible lesions included de novo lesions as well as re-stenotic and re-occluded lesions.
By examining the use of radial access for these procedures, the study adds to the growing clinical interest in alternative vascular access strategies. For physicians, having multiple access options can be valuable when anatomical or clinical considerations make a conventional approach less suitable.
100% Procedural Success Reported
One of the key findings from the BIONETIC-TRA study was a 100% procedural success rate using radial access with the Dynetic™-35 Stent. The result supports the feasibility of delivering the device through a trans-radial route for iliac artery interventions.
Dr. Michael Lichtenberg, who led the study, said the findings support the trans-radial approach as an alternative strategy, particularly for patients in whom femoral access may be difficult or contraindicated.
The findings are significant because iliac artery interventions can require devices and delivery systems capable of navigating relatively long vascular pathways when access is obtained through the radial artery. Device profile, delivery length, flexibility and support therefore become important considerations when physicians evaluate whether a trans-radial strategy is appropriate.
The clinical experience generated through the BIONETIC-TRA study provides additional insight into these procedural considerations and demonstrates the potential of combining radial access with a stent system designed to accommodate the requirements of iliac interventions.
Dynetic™-35 Designed for Trans-Radial Use
The Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System incorporates several features intended to support endovascular treatment.
The stent is manufactured from a cobalt chromium alloy, a material selected for its mechanical properties and ability to provide substantial radial strength. Radial strength is particularly important in vascular stenting because the implanted device must help maintain vessel patency against the forces exerted by the arterial wall.
The Dynetic™-35 also incorporates proBIO™ Coating, another feature of the device platform. In addition, the system is compatible with 6F delivery systems and is available in usable lengths of up to 170 centimeters.
The combination of these characteristics is intended to facilitate delivery from the radial artery to the iliac arteries. The extended usable length is especially relevant when physicians approach iliac lesions from an upper-extremity access point, as the distance from the radial artery to the target treatment site can be considerably greater than with femoral access.
By combining a relatively low-profile delivery configuration with an extended working length, the system is designed to provide physicians with greater flexibility when considering trans-radial intervention.
Addressing the Need for Alternative Access Strategies
The growing interest in alternative vascular access approaches reflects broader efforts within interventional medicine to improve procedural flexibility and patient management.
Radial access is widely recognized in several areas of cardiovascular intervention, but its use for peripheral vascular procedures, including iliac interventions, can involve different technical requirements. The anatomy, distance to the treatment site and equipment needed for the procedure all influence whether radial access is practical.
Teleflex believes technologies such as the Dynetic™-35 can help address some of these requirements by providing device configurations suitable for procedures performed through radial access.
Prof. Dr. Georg Nollert, Vice President of Medical Affairs at Teleflex, emphasized that clinical data and device configurations specifically supporting the treatment of iliac disease through trans-radial access have historically been limited.
According to Nollert, Teleflex is focused on developing low-profile catheter-based technologies that can provide physicians with alternative access options and potentially broaden procedural choices for patients.
Favorable Radial Access Experience
In addition to the reported procedural success, the BIONETIC-TRA study provided information regarding the practical use of trans-radial access.
The approach was associated with a low rate of asymptomatic radial artery occlusion, an important consideration when assessing the safety and practicality of radial access. Radial artery occlusion can occur following trans-radial procedures, although asymptomatic cases may not result in noticeable clinical consequences for patients.
The investigators also reported a non-complex learning curve associated with the trans-radial approach. This observation may be relevant as physicians and interventional teams evaluate the integration of alternative access techniques into their procedural practices.
However, as with any vascular intervention, patient selection, anatomical characteristics and physician experience remain important factors in determining the most appropriate access route. The availability of an alternative does not necessarily mean that radial access will be suitable for every patient or every iliac lesion.
Potential Benefits for Complex Patient Populations
Patients with peripheral arterial disease frequently present with multiple anatomical and clinical challenges. Calcification, stenosis and previous interventions can complicate access and treatment planning.
For older patients and individuals with critical limb ischemia, minimizing procedural complications is an important component of treatment planning. Avoiding a potentially problematic femoral access site may offer an alternative in selected cases.
A trans-radial strategy may also provide physicians with another option when femoral arteries are heavily diseased or otherwise unsuitable for catheter access.
The BIONETIC-TRA study therefore contributes to a broader discussion about how access-site selection can be individualized according to patient characteristics and procedural requirements.
The findings do not establish trans-radial access as a replacement for femoral access in all iliac procedures. Instead, they support the concept that physicians may benefit from having additional access strategies available when conventional approaches are challenging.
Teleflex Showcases Innovation at CIRSE 2026
Teleflex’s presentation at CIRSE 2026 reflects the company’s broader investment in minimally invasive medical technologies and catheter-based solutions.
The CIRSE meeting provides a platform for physicians, researchers and medical technology companies to exchange clinical experiences and discuss advances in interventional radiology. By highlighting the Dynetic™-35 system and the findings from the BIONETIC-TRA study, Teleflex is bringing attention to the potential role of trans-radial access in iliac artery interventions.
The company’s participation also highlights the importance of combining device engineering with clinical evidence. For interventional physicians, device specifications alone may not determine whether a technology is useful in clinical practice. Evidence demonstrating procedural feasibility, safety and usability can be equally important when considering new treatment approaches.
The BIONETIC-TRA study provides early clinical experience supporting the use of the Dynetic™-35 through radial access, while the device’s cobalt chromium construction, proBIO™ Coating, 6F compatibility and 170-centimeter usable length are intended to address some of the technical demands associated with this approach.
Continuing Development of Vascular Treatment Options
Teleflex’s focus on alternative access and low-profile catheter-based technologies reflects an ongoing evolution in endovascular treatment. As minimally invasive interventions become increasingly important in the management of vascular disease, physicians continue to seek technologies that can accommodate different patient anatomies and procedural circumstances.
The ability to select between femoral, radial and other access routes can give physicians greater flexibility when planning interventions. This can be especially valuable in patients with extensive peripheral vascular disease, prior procedures or anatomical factors that make traditional access more complicated.
The experience from the BIONETIC-TRA study represents one contribution to this evolving field. With a reported 100% procedural success rate through radial access, low rates of asymptomatic radial artery occlusion and a non-complex learning curve, the study provides encouraging evidence regarding the feasibility of this strategy with the Dynetic™-35 system.
As Teleflex showcases the technology at CIRSE 2026, the company is positioning the Dynetic™-35 as part of its broader portfolio of catheter-based solutions aimed at giving physicians additional options for minimally invasive vascular care.
Ultimately, continued clinical evaluation will be important in determining how trans-radial iliac interventions fit into routine practice and which patient populations may benefit most. For selected patients where femoral access is difficult or contraindicated, the combination of radial access and appropriately designed stent technology could represent a valuable alternative in the treatment of iliac artery disease.
About the Dynetic™-35 Peripheral Balloon-Expandable Stent System
The Dynetic™-35 Peripheral Balloon-Expandable Stent System is a permanent implant constructed from cobalt chromium alloy (L-605) with a proBIO™ Coating (amorphous silicon carbide). It is pre-mounted on an over-the-wire PTA balloon catheter delivery system, available in a broad size range for treatment of iliac artery lesions, distributed by Teleflex in selected countries.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.